Notably, the recent failures of FRα-targeted therapies in clinical trials with ovarian cancer patients (Table 1) reflect, at least in part, the challenge in identifying FRα-positivity, hence the patients most likely to respond to FR-targeted treatments. The gene discussed is FOLR1; the disease is ovarian cancer.